Bli medlem
Bli medlem

Du är här

2015-04-23

Active Biotech: Active Biotech AB Interim report January - March 2015

Laquinimod

* The pivotal CONCERTO clinical study is continuing according to plan and
results are expected in 2016
* Teva is holding a number of presentations of laquinimod at the AAN Annual
Meeting on April 18-25

Tasquinimod

* Results from the Phase III study 10TASQ10 showed that treatment with
tasquinimod reduced the risk of radiographic cancer progression or death
compared to placebo (rPFS, HR=0.69, CI 95%: 0.60 - 0.80) in patients with
metastatic castration resistant prostate cancer (mCRPC) who have not
received chemotherapy, but did not extend overall survival (OS, HR=1.09, CI
95%: 0.94 - 1.28)
* Further development of tasquinimod for the treatment of prostate cancer has
been discontinued. The collaboration agreement with Ipsen will accordingly
cease.

ISI

* The project is currently focusing on building up a patent portfolio

Financial summary

----------------------------------------------------------
| MSEK Jan. - Mar. Jan. - Dec. |
| 2015 2014 2014 |
| Net sales 2.9 2.1 10.4 |
| |
| Operating loss -57.4 -59.2 -228.5 |
| Loss for the period -58.0 -60.2 -231.5 |
| Loss per share (SEK) -0.64 -0.80 -3.02 |
| Cash and cash equivalents 270.5 298.5 328.5 |
----------------------------------------------------------
For further information, please contact:

--------------------------------------------------------------------------------------
| Tomas Leanderson, President and CEO Active Biotech AB |
| Tel: +46 (0)46 19 20 95 |
| (Corp. Reg. No. 556223-9227) |
| Box 724, SE-220 07 Lund |
| Tel: +46 (0)46 19 20 00 |
| Hans Kolam, CFO Fax: +46 (0)46 19 11 00 |
| Tel: +46 (0)46 19 20 44 |
| The report is also available atwww.activebiotech.com |
--------------------------------------------------------------------------------------
Active Biotech AB Interim report January - March 2015
http://hugin.info/1002/R/1913651/683571.pdf

---------------------------------------

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Active Biotech via Globenewswire

HUG#1913651

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.